161 related articles for article (PubMed ID: 1991682)
1. Interaction of platinum drugs with clinically relevant x-ray doses in mammalian cells: a comparison of cisplatin, carboplatin, iproplatin, and tetraplatin.
Skov K; MacPhail S
Int J Radiat Oncol Biol Phys; 1991 Feb; 20(2):221-5. PubMed ID: 1991682
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of radiation-induced cell kill by platinum complexes (carboplatin and iproplatin) in V79 cells.
O'Hara JA; Douple EB; Richmond RC
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1419-22. PubMed ID: 3531116
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.
Groen HJ; Sleijfer S; Meijer C; Kampinga HH; Konings AW; De Vries EG; Mulder NH
Br J Cancer; 1995 Dec; 72(6):1406-11. PubMed ID: 8519652
[TBL] [Abstract][Full Text] [Related]
4. Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition.
Amorino GP; Freeman ML; Carbone DP; Lebwohl DE; Choy H
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):399-405. PubMed ID: 10760436
[TBL] [Abstract][Full Text] [Related]
5. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
Mellish KJ; Kelland LR; Harrap KR
Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
[TBL] [Abstract][Full Text] [Related]
6. The influence of platinum drugs on the radiation response of rat kidneys.
van Rongen E; Kuijpers WC; Baten-Wittwer A
Radiother Oncol; 1994 May; 31(2):138-50. PubMed ID: 8066193
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin as a potentiator of radiation therapy.
Douple EB; Richmond RC; O'Hara JA; Coughlin CT
Cancer Treat Rev; 1985 Sep; 12 Suppl A():111-24. PubMed ID: 3910216
[TBL] [Abstract][Full Text] [Related]
8. Intracellular glutathione and cytotoxicity of platinum complexes.
Pendyala L; Creaven PJ; Perez R; Zdanowicz JR; Raghavan D
Cancer Chemother Pharmacol; 1995; 36(4):271-8. PubMed ID: 7628045
[TBL] [Abstract][Full Text] [Related]
9. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
Perez RP; O'Dwyer PJ; Handel LM; Ozols RF; Hamilton TC
Int J Cancer; 1991 May; 48(2):265-9. PubMed ID: 2019469
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
Orr RM; O'Neill CF; Nicolson MC; Barnard CF; Murrer BA; Giandomenico CM; Vollano JF; Harrap KR
Br J Cancer; 1994 Sep; 70(3):415-20. PubMed ID: 8080724
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
Rixe O; Ortuzar W; Alvarez M; Parker R; Reed E; Paull K; Fojo T
Biochem Pharmacol; 1996 Dec; 52(12):1855-65. PubMed ID: 8951344
[TBL] [Abstract][Full Text] [Related]
12. The mutagenic and carcinogenic properties of three second generation antitumour platinum compounds: a comparison with cisplatin.
Chibber R; Ord MJ
Eur J Cancer Clin Oncol; 1989 Jan; 25(1):27-33. PubMed ID: 2646132
[TBL] [Abstract][Full Text] [Related]
13. Interaction of D,L- and D-tetraplatin with hyperthermia in vitro and in vivo.
Epelbaum R; Teicher BA; Holden SA; Ara G; Varshney A; Herman TS
Eur J Cancer; 1992; 28A(4-5):794-800. PubMed ID: 1524897
[TBL] [Abstract][Full Text] [Related]
14. Low concentrations of nitroimidazoles: effective radiosensitizers at low doses.
Skov KA; MacPhail S
Int J Radiat Oncol Biol Phys; 1994 Apr; 29(1):87-93. PubMed ID: 8175450
[TBL] [Abstract][Full Text] [Related]
15. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.
Kelland LR; Jones M; Abel G; Valenti M; Gwynne J; Harrap KR
Cancer Chemother Pharmacol; 1992; 30(1):43-50. PubMed ID: 1586979
[TBL] [Abstract][Full Text] [Related]
16. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of hypoxic cells by cisplatin and radiation at clinically relevant doses.
Korbelik M; Skov KA
Radiat Res; 1989 Jul; 119(1):145-56. PubMed ID: 2756105
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitizing and toxic properties of quinoline and nitroquinoline complexes of platinum [PtCl2(NH3)quinoline].
Skov KA; Adomat H; Doedee M; Farrell N
Anticancer Drug Des; 1994 Apr; 9(2):103-17. PubMed ID: 8166927
[TBL] [Abstract][Full Text] [Related]
19. Lung tumour growth delay and normal tissue toxicity induced by three cytotoxic platinum drugs.
van Rongen E; Kal HB; Kuijpers WC; van Berkel AH
Strahlenther Onkol; 1992 May; 168(5):300-7. PubMed ID: 1598667
[TBL] [Abstract][Full Text] [Related]
20. Comparative toxicity and renal distribution of the platinum analogs tetraplatin, CHIP, and cisplatin at equimolar doses in the Fischer 344 rat.
Smith JH; Smith MA; Litterst CL; Copley MP; Uozumi J; Boyd MR
Fundam Appl Toxicol; 1988 Jan; 10(1):45-61. PubMed ID: 3350229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]